The stock of Maze Therapeutics Inc (MAZE) has seen a -1.57% decrease in the past week, with a 8.22% gain in the past month, and a -18.15% decrease in the past quarter. The volatility ratio for the week is 12.83%, and the volatility levels for the past 30 days are at 7.02% for MAZE. The simple moving average for the past 20 days is -1.23% for MAZE’s stock, with a -6.60% simple moving average for the past 200 days.
Is It Worth Investing in Maze Therapeutics Inc (NASDAQ: MAZE) Right Now?
Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MAZE is 13.08M, and currently, short sellers hold a 15.51% ratio of that float. The average trading volume of MAZE on June 02, 2025 was 219.31K shares.
MAZE) stock’s latest price update
The stock price of Maze Therapeutics Inc (NASDAQ: MAZE) has dropped by -17.75 compared to previous close of 12.17. Despite this, the company has seen a fall of -1.57% in its stock price over the last five trading days. globenewswire.com reported 2025-05-29 that SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that Jason Coloma, Ph.D.
MAZE Trading at 2.78% from the 50-Day Moving Average
After a stumble in the market that brought MAZE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.12% of loss for the given period.
Volatility was left at 7.02%, however, over the last 30 days, the volatility rate increased by 12.83%, as shares sank -5.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.55% lower at present.
During the last 5 trading sessions, MAZE fell by -1.57%, in comparison to the 20-day moving average, which settled at $10.14. In addition, Maze Therapeutics Inc saw -37.24% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MAZE
Current profitability levels for the company are sitting at:
- -44.96 for the present operating margin
- 1.0 for the gross margin
The net margin for Maze Therapeutics Inc stands at -32.36. The total capital return value is set at -0.36.
Based on Maze Therapeutics Inc (MAZE), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -3.71.
Currently, EBITDA for the company is 60.88 million with net debt to EBITDA at 2.44. When we switch over and look at the enterprise to sales, we see a ratio of 67.94. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.10.
Conclusion
To put it simply, Maze Therapeutics Inc (MAZE) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
